Exscientia (NASDAQ:EXAI) Stock Price Up 6.9%

Exscientia plc (NASDAQ:EXAI)’s stock price rose 6.9% during mid-day trading on Monday . The stock traded as high as $5.01 and last traded at $4.99. Approximately 341,928 shares traded hands during mid-day trading, a decline of 50% from the average daily volume of 686,375 shares. The stock had previously closed at $4.67.

Analyst Ratings Changes

Separately, Morgan Stanley reissued an “equal weight” rating and issued a $7.00 price objective on shares of Exscientia in a research note on Monday, April 22nd.

Exscientia Price Performance

The company has a current ratio of 6.22, a quick ratio of 6.22 and a debt-to-equity ratio of 0.05. The firm has a market cap of $565.77 million, a P/E ratio of -3.13 and a beta of 0.82. The firm has a 50-day simple moving average of $5.33 and a 200-day simple moving average of $5.81.

Exscientia (NASDAQ:EXAI) last announced its earnings results on Thursday, March 21st. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.02. The business had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $41.63 million. Exscientia had a negative return on equity of 36.44% and a negative net margin of 737.10%. As a group, analysts forecast that Exscientia plc will post -1.76 EPS for the current year.

Institutional Trading of Exscientia

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Platinum Investment Management Ltd. lifted its holdings in shares of Exscientia by 10.2% during the 3rd quarter. Platinum Investment Management Ltd. now owns 4,395,058 shares of the company’s stock valued at $19,866,000 after purchasing an additional 405,426 shares during the last quarter. Banque Pictet & Cie SA purchased a new position in Exscientia in the 3rd quarter worth $1,040,000. Federated Hermes Inc. purchased a new position in Exscientia in the 3rd quarter worth $362,000. DekaBank Deutsche Girozentrale purchased a new position in Exscientia in the 3rd quarter worth $344,000. Finally, Jump Financial LLC purchased a new position in Exscientia in the 3rd quarter worth $165,000. Institutional investors own 41.58% of the company’s stock.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.